Retatrutide, GLP-1s and triple-agonist biology
How incretin research moved from single to triple receptor targets.
Research context
GLP-1 receptor agonists reshaped metabolic research. Newer compounds target GLP-1, GIP and glucagon receptors together, an approach under active clinical investigation.
Reading the evidence
Much of the available literature comes from cell and animal models. Findings should be read with attention to study design, sample size and whether results have been independently replicated.
A note on use
Silsila products are presented for laboratory research only. Nothing in this journal is medical advice, and no product is intended for human or veterinary use.
Sources & evidence
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
This trial studied an investigational GIP, GLP-1 and glucagon receptor agonist. A phase 2 publication does not establish approval.
Read original sourceA study indexed in PubMed or hosted on PMC is not NIH or FDA approval. Findings for approved medicines do not establish the safety or effectiveness of Silsila products.